Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Matthew A, Cerny"'
Publikováno v:
Drug Metabolism and Disposition. 51:647-656
Autor:
Christine C. Orozco, Mikko Neuvonen, Yi-An Bi, Matthew A. Cerny, Sumathy Mathialagan, Laurie Tylaska, Brian Rago, Chester Costales, Amanda King-Ahmad, Mikko Niemi, A. David Rodrigues
Publikováno v:
Molecular Pharmaceutics.
Autor:
David Rodrigues, Mark Niosi, Heather Eng, Christopher Healy, Sarah Lazzaro, Qingyi Yang, Matthew A. Cerny
Publikováno v:
The Journal of Clinical Pharmacology.
Autor:
Heather Eng, Theunis C. Goosen, Jian Lin, Matthew A. Cerny, R. Scott Obach, Elaine E. Tseng, David A. Tess
Publikováno v:
Drug Metabolism and Disposition. 49:947-960
Cytochrome P450 3A (CYP3A) is a frequent target for time-dependent inhibition (TDI) that can give rise to drug-drug interactions (DDI). Yet many drugs that exhibit in vitro TDI for CYP3A do not result in DDI. There were 23 drugs with published clinic
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 49(6)
Time-dependent inhibition (TDI) of CYP3A is an important mechanism underlying numerous drug-drug interactions (DDIs), and assays to measure this are done to support early drug research efforts. However, measuring TDI of CYP3A in human liver microsome
Autor:
Matthew A. Cerny, A. David Rodrigues, Brian Rago, Sarah Lazzaro, Ragu Ramanathan, Chester Costales, Mikko Neuvonen, Aleksi Tornio, Manthena V.S. Varma, Mark A. West, Sumathy Mathialagan, Päivi Hirvensalo, Mikko Niemi
Publikováno v:
Clinical Pharmacology and Therapeutics
The aim of this study was to investigate the sensitivity and specificity of endogenous glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides (GCDCA-3G and GDCA-3G) as substrates for organic anion transporting polypeptide 1B1 (OATP1B1) in huma
Autor:
R. Scott Obach, Amit S. Kalgutkar, Gregory S. Walker, Matthew A. Cerny, Raman Sharma, Douglas K. Spracklin
Publikováno v:
Journal of medicinal chemistry. 63(12)
At one time, biotransformation was a descriptive activity in pharmaceutical development, viewed simply as structural elucidation of drug metabolites, completed only once compounds entered clinical development. Herein, we present our strategic approac
Autor:
Neil Moss, Lee Fader, Jeremy R Richman, Stanley Kugler, Matthew A. Cerny, Jennifer Burke, Raquel Arenas, Derek Cogan, Federico Colombo, Maolin Yu, Kosea Frederick, John Lord, Zhidong Chen, Jean-Huges Parmentier, Balestra Michael, Nicholas F. Brown, Steven M. Weldon, Xin Guo, Daniel R. Goldberg, Michael Zhang, Holly Clifford, Jennifer Schmenk, Kenneth M. Meyers, Daniel Richard Marshall, Keith R Hornberger
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 28:979-984
6,7-Dihydro-5H-2,1-benzisoxazol-4-one analogs are potent inhibitors of aldosterone synthase (CYP11B2) with selectivity over the highly homologous enzyme cortisol synthase (CYP11B1). These compounds are unique among inhibitors of CYP11B2 in their lack
Autor:
Ryan M, Fryer, Khing Jow, Ng, Suzanne G, Nodop Mazurek, Lori, Patnaude, Donna J, Skow, Akalushi, Muthukumarana, Kyle E, Gilpin, Roger M, Dinallo, Daniel, Kuzmich, John, Lord, Sulagna, Sanyal, Hui, Yu, Christian, Harcken, Matthew A, Cerny, Matthew C, Cerny, Eugene R, Hickey, Louise K, Modis
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 348:421-431
Bile acids (BAs) and BA receptors, including G protein-coupled bile acid receptor 1 (GPBAR1), represent novel targets for the treatment of metabolic and inflammatory disorders. However, BAs elicit myriad effects on cardiovascular function, although t
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 154:197-205
Elevated levels of aldosterone are associated with arterial hypertension, congestive heart failure, chronic kidney disease, and obesity. Aldosterone is produced predominantly in the zona glomerulosa of the cortex of the adrenal gland by the enzyme al